Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
11.08 (1y: +12%)
Market Cap 349.26 M P/E(ttm)
Enterprise Value 421 M P/B 0.77
AMED- NAS (USA)
Amedisys, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$11.08
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.142
AMED's Cash to Debt is ranked higher than
51% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. AMED: 0.142 )
AMED' s 10-Year Cash to Debt Range
Min: 0.01   Max: 23.47
Current: 0.14
0.01
23.47
Equity to Asset 0.268
AMED's Equity to Asset is ranked lower than
59% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.26 vs. AMED: 0.268 )
AMED' s 10-Year Equity to Asset Range
Min: -0.26   Max: 0.41
Current: 0.27
-0.26
0.41
F-Score: 4
Z-Score: 2.24
M-Score: -3.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -7.50
AMED's Operating margin (%) is ranked lower than
68% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 7.30 vs. AMED: -7.50 )
AMED' s 10-Year Operating margin (%) Range
Min: -76.9   Max: 15.2
Current: -7.5
-76.9
15.2
Net-margin (%) -5.6
AMED's Net-margin (%) is ranked lower than
56% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. AMED: -5.6 )
AMED' s 10-Year Net-margin (%) Range
Min: -65.3   Max: 9.3
Current: -5.6
-65.3
9.3
ROE (%) -18.5
AMED's ROE (%) is ranked lower than
58% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.20 vs. AMED: -18.5 )
AMED' s 10-Year ROE (%) Range
Min: -73.7   Max: 162.8
Current: -18.5
-73.7
162.8
ROA (%) -11.4
AMED's ROA (%) is ranked lower than
51% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.60 vs. AMED: -11.4 )
AMED' s 10-Year ROA (%) Range
Min: -56   Max: 15.3
Current: -11.4
-56
15.3
ROC (Joel Greenblatt) (%) -62.70
AMED's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 17.40 vs. AMED: -62.70 )
AMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -325.4   Max: 521.3
Current: -62.7
-325.4
521.3
Revenue Growth (%) -2.3
AMED's Revenue Growth (%) is ranked higher than
60% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.50 vs. AMED: -2.3 )
AMED' s 10-Year Revenue Growth (%) Range
Min: -17.8   Max: 25.3
Current: -2.3
-17.8
25.3
» AMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

AMED Guru Trades in Q2 2012

Charles Brandes 20,910 sh (+3.54%)
Paul Tudor Jones Sold Out
John Hussman Sold Out
Joel Greenblatt 129,373 sh (-10.66%)
Jim Simons 250,400 sh (-46.75%)
Chuck Royce 2,000 sh (-58.33%)
Steven Cohen 12,121 sh (-73.36%)
» More
Q3 2012

AMED Guru Trades in Q3 2012

Steven Cohen 12,610 sh (+4.03%)
Chuck Royce 2,000 sh (unchged)
Charles Brandes Sold Out
Jim Simons 241,500 sh (-3.55%)
Joel Greenblatt 65,015 sh (-49.75%)
» More
Q4 2012

AMED Guru Trades in Q4 2012

Charles Brandes 36,685 sh (New)
Paul Tudor Jones 13,000 sh (New)
Chuck Royce Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Jim Simons 162,801 sh (-32.59%)
» More
Q1 2013

AMED Guru Trades in Q1 2013

Charles Brandes 225,885 sh (+515.74%)
Paul Tudor Jones 18,300 sh (+40.77%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMED

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2013-03-31 Add 515.74%0.03%$10.95 - $13.11 $ 11.08-5%225885
Joel Greenblatt 2012-12-31 Sold Out 0.06%$9.65 - $13.56 $ 11.08-2%0
Charles Brandes 2012-12-31 New Buy$9.65 - $13.56 $ 11.08-2%36685
Joel Greenblatt 2012-09-30 Reduce -49.75%0.06%$11.3 - $15.84 $ 11.08-19%65015
Charles Brandes 2012-09-30 Sold Out 0.0017%$11.3 - $15.84 $ 11.08-19%0
John Hussman 2012-06-30 Sold Out 0.04%$9.87 - $15.03 $ 11.08-11%0
Joel Greenblatt 2012-03-31 Add 98.71%0.09%$9.56 - $14.66 $ 11.081%144813
Charles Brandes 2012-03-31 New Buy$9.56 - $14.66 $ 11.081%20195
David Dreman 2011-12-31 Sold Out 0.5%$9.59 - $14.56 $ 11.08-6%0
George Soros 2011-12-31 Sold Out 0.0041%$9.59 - $14.56 $ 11.08-6%0
Charles Brandes 2011-12-31 Sold Out 0.0021%$9.59 - $14.56 $ 11.08-6%0
Joel Greenblatt 2011-09-30 Add 125.99%0.09%$13.29 - $27.55 $ 11.08-44%64379
George Soros 2011-09-30 Reduce -91.93%0.07%$13.29 - $27.55 $ 11.08-44%16100
Ronald Muhlenkamp 2011-06-30 Sold Out 1.15%$25.28 - $35.18 $ 11.08-64%0
George Soros 2011-06-30 New Buy0.07%$25.28 - $35.18 $ 11.08-64%199599
Joel Greenblatt 2011-06-30 Add 21.45%0.02%$25.28 - $35.18 $ 11.08-64%28488
Charles Brandes 2011-06-30 New Buy$25.28 - $35.18 $ 11.08-64%14350
Joel Greenblatt 2011-03-31 Reduce -60.67%0.39%$31.01 - $38.08 $ 11.08-68%23456
Ronald Muhlenkamp 2011-03-31 Reduce -24.51%0.37%$31.01 - $38.08 $ 11.08-68%225300
John Hussman 2011-03-31 Reduce -52.13%0.1%$31.01 - $38.08 $ 11.08-68%146000
Mario Gabelli 2011-03-31 Sold Out $31.01 - $38.08 $ 11.08-68%0
Ronald Muhlenkamp 2010-12-31 Reduce -61.09%2.21%$23.47 - $34.25 $ 11.08-60%298460
Joel Greenblatt 2010-12-31 New Buy0.65%$23.47 - $34.25 $ 11.08-60%59637
Ronald Muhlenkamp 2010-09-30 Add 106.63%1.59%$23.15 - $37.8 $ 11.08-58%767030
David Dreman 2010-09-30 Add 91.72%0.29%$23.15 - $37.8 $ 11.08-58%1110300
George Soros 2010-09-30 Sold Out 0.01%$23.15 - $37.8 $ 11.08-58%0
John Hussman 2010-06-30 New Buy0.23%$42.31 - $62.99 $ 11.08-79%305000
David Dreman 2010-06-30 Add 21.88%0.12%$42.31 - $62.99 $ 11.08-79%579113
George Soros 2010-06-30 New Buy0.01%$42.31 - $62.99 $ 11.08-79%8700
Mario Gabelli 2010-06-30 Reduce -41.18%$42.31 - $62.99 $ 11.08-79%10000
David Dreman 2010-03-31 Reduce -23.88%0.15%$48.6 - $61.53 $ 11.08-80%475163
George Soros 2010-03-31 Sold Out 0.01%$48.6 - $61.53 $ 11.08-80%0
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 0.80
AMED's P/B is ranked higher than
88% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.99 vs. AMED: 0.80 )
AMED' s 10-Year P/B Range
Min: 0.48   Max: 75
Current: 0.8
0.48
75
P/S 0.20
AMED's P/S is ranked higher than
94% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.81 vs. AMED: 0.20 )
AMED' s 10-Year P/S Range
Min: 0.15   Max: 2.36
Current: 0.2
0.15
2.36
PFCF 15.40
AMED's PFCF is ranked higher than
87% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 14.34 vs. AMED: 15.40 )
AMED' s 10-Year PFCF Range
Min: 2.68   Max: 89.91
Current: 15.4
2.68
89.91
EV-to-EBIT 5.2
AMED's EV-to-EBIT is ranked higher than
92% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 13.20 vs. AMED: 5.2 )
AMED' s 10-Year EV-to-EBIT Range
Min: 3.1   Max: 1136.6
Current: 5.2
3.1
1136.6
Shiller P/E 17.4
AMED's Shiller P/E is ranked higher than
89% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.50 vs. AMED: 17.4 )
AMED' s 10-Year Shiller P/E Range
Min: 4.83   Max: 223.66
Current: 17.4
4.83
223.66

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 2.9
AMED's Price/Net Current Asset Value is ranked higher than
54% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 6.55 vs. AMED: 2.9 )
AMED' s 10-Year Price/Net Current Asset Value Range
Min: 2.9   Max: 23.3
Current: 2.9
2.9
23.3
Price/Tangible Book 1.8
AMED's Price/Tangible Book is ranked higher than
78% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 2.70 vs. AMED: 1.8 )
AMED' s 10-Year Price/Tangible Book Range
Min: 1.7   Max: 28.9
Current: 1.8
1.7
28.9
Price/DCF (Projected) 0.2
AMED's Price/DCF (Projected) is ranked higher than
65% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.80 vs. AMED: 0.2 )
AMED' s 10-Year Price/DCF (Projected) Range
Min: 0.2   Max: 2.5
Current: 0.2
0.2
2.5
Price/Median PS Value 0.3
AMED's Price/Median PS Value is ranked lower than
71% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.90 vs. AMED: 0.3 )
AMED' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.9
Current: 0.3
0.3
2.9
Earnings Yield (Greenblatt) 19.20
AMED's Earnings Yield (Greenblatt) is ranked higher than
91% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. AMED: 19.20 )
AMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 32.2
Current: 19.2
0.1
32.2
Forward Rate of Return (Yacktman) 31.82
AMED's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.99 vs. AMED: 31.82 )
AMED' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.3   Max: 50.7
Current: 31.82
-4.3
50.7

Business Description

Amedisys, Inc. was originally incorporated in Louisiana in 1982. Its operations were transferred to a Delaware corporation, which was incorporated in 1994; and became a publicly traded company in August of that year. The Company is a health care company engaged in delivering personalized health care services to patients and their families. Its chronic care management programs and innovative technology infrastructure enable it to deliver quality care based upon the latest evidence-based best practices. It also has one of the industry's first nationwide Care Transitions program. Its Care Transitions is designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues through completion of the patient's home health plan of care. As of December 31, 2011, it owned and operated 440 Medicare-certified home health care centers, 87 Medicare-certified hospice care centers and two hospice inpatient units in 41 states within the United States, the District of Columbia and Puerto Rico. Its services are mainly paid for by Medicare due to the age demographics of its patient base (average age 81). The Company's main competition in these jurisdictions comes from local privately-owned and hospital-owned health care providers. In addition, it competes with a number of non-profit organizations. The Company is subject to Federal, state and local laws and regulations.
Company Website
SEC Reports
Industry: Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF
» More Articles for AMED

Headlines

Articles On GuruFocus.com
“Powerball” Ideas - Home Healthcare Companies: AFAM, GTIV, LHCG, AMED Jan 05 2012 
AMED: Investment Opportunity When the Price Hits an 8-Year Low Dec 27 2011 
Almost Family: The Magic Formula Stock is getting cheaper and cheaper Dec 11 2011 
Magic Formula Stock: Amedisys (AMED) Aug 05 2011 
Value Investing Seminar: Oliver Mihaljevic-Magic Formula Education Stocks Jul 13 2011 
Home Healthcare: Heavily Shorted long Opportunity May 30 2011 
Amedisys Inc (AMED) CFO Dale E Redman buys 1,000 Shares Aug 25 2010 
Amedisys Inc Reports Operating Results (10-Q) Aug 09 2010 
Amedisys Inc Reports Operating Results (10-Q) Apr 27 2010 
MFI STOCK REVIEW: ODYSSEY HEALTHCARE INC Feb 25 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial